These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28303528)

  • 41. Niraparib - A promising drug with hematological toxicity.
    Patibandla NS; Monga DK
    J Oncol Pharm Pract; 2019 Oct; 25(7):1749-1753. PubMed ID: 30293481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    McCann KE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
    Jones P; Wilcoxen K; Rowley M; Toniatti C
    J Med Chem; 2015 Apr; 58(8):3302-14. PubMed ID: 25761096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Mirza MR; Pignata S; Ledermann JA
    Ann Oncol; 2018 Jun; 29(6):1366-1376. PubMed ID: 29750420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Niraparib Slows Ovarian Cancer Progression.
    Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
    Park J; Lim MC; Lee JK; Jeong DH; Kim SI; Choi MC; Kim BG; Lee JY
    J Gynecol Oncol; 2022 Mar; 33(2):e12. PubMed ID: 34910393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
    Liu J; Hawkes C; Walder L; Spalding C; Travers K; Maiese EM; Hurteau J
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1377-1387. PubMed ID: 34595950
    [No Abstract]   [Full Text] [Related]  

  • 48. Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma.
    Ji Y; Wang Q; Zhao Q; Zhao S; Li L; Sun G; Ye L
    Appl Microbiol Biotechnol; 2019 Dec; 103(23-24):9557-9568. PubMed ID: 31686145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.
    Yonemori K; Shimizu T; Kondo S; Iwasa S; Koyama T; Kitano S; Sato J; Shimomura A; Shibaki R; Suri A; Kase Y; Sumino S; Tamura K; Yamamoto N
    Jpn J Clin Oncol; 2021 Apr; 51(5):693-699. PubMed ID: 33621324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 'PARP'ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors.
    Rao PD; Sankrityayan H; Srivastava A; Kulkarni YA; Mulay SR; Gaikwad AB
    Drug Discov Today; 2020 Jul; 25(7):1253-1261. PubMed ID: 32371137
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Eakin CM; Ewongwo A; Pendleton L; Monk BJ; Chase DM
    Gynecol Oncol; 2020 Oct; 159(1):112-117. PubMed ID: 32811682
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy.
    Liu MC; Sutedja J; Tewari KS
    Expert Rev Anticancer Ther; 2021 May; 21(5):475-480. PubMed ID: 33691564
    [No Abstract]   [Full Text] [Related]  

  • 53. Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.
    Smith JA; Le T; Martin GA; Gaikwad A; Sun CH; Nugent EK; Lucci JA
    Gynecol Oncol; 2019 Feb; 152(2):265-269. PubMed ID: 30466807
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers.
    Bian Y; Meng J; Ma S; Li G; Wang Y; Li S; Liu L; Huang C; Zhang H; Zhong D; Miao L
    Br J Clin Pharmacol; 2022 Jul; 88(7):3307-3320. PubMed ID: 35112382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two 'long responder' case reports and review of the current literature.
    Ngan RKC
    J Int Med Res; 2023 Sep; 51(9):3000605231194881. PubMed ID: 37676922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of niraparib for the treatment of ovarian cancer.
    Ethier JL; Lheureux S; Oza AM
    Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma.
    Zai W; Chen W; Han Y; Wu Z; Fan J; Zhang X; Luan J; Tang S; Jin X; Fu X; Gao H; Ju D; Liu H
    Carcinogenesis; 2020 May; 41(3):345-357. PubMed ID: 31175354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.